Zegerid (Original Formulation) (omeprazole) Disease Interactions
There are 3 disease interactions with Zegerid (Original Formulation) (omeprazole):
PPIs (Includes Zegerid (Original Formulation)) ↔ C. diff
Severe Potential Hazard, Moderate plausibility. Applies to: Pseudomembranous Colitis, Diarrhea
Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Proton pump inhibitors (Includes Zegerid (Original Formulation)) ↔ bone fractures
Moderate Potential Hazard, Moderate plausibility. Applies to: Osteoporosis
Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.
Proton pump inhibitors (Includes Zegerid (Original Formulation)) ↔ hypomagnesemia
Moderate Potential Hazard, Moderate plausibility. Applies to: Magnesium Imbalance
Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.
Zegerid (Original Formulation) (omeprazole) drug interactions
There are 344 drug interactions with Zegerid (Original Formulation) (omeprazole)
More about Zegerid (Original Formulation) (omeprazole)
- Zegerid (Original Formulation) Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Drug class: proton pump inhibitors
- FDA Alerts (6)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.